natgillin/translations-raw huggingface dataset:
Following subcutaneous administration of daclizumab beta 150 mg every 4 weeks, steady-state serum daclizumab beta concentrations were achieved by the 4th dose and daclizumab beta accumulated to a level approximately 2.5-fold compared to a single dose. 
Po subkutani uporabi daklizumaba beta 150 mg vsake 4 tedne je bilo stanje dinamičnega ravnovesja koncentracij daklizumaba beta v serumu doseženo do 4. odmerka; daklizumab beta se je akumuliral do ravni, ki je bila približno 2,5-kratnik v primerjavi z enkratnim odmerkom.
There is also a plausible mechanism of action for the development of sarcoidosis due to the immunomodulatory effects of daclizumab beta and involvement of daclizumab beta in the origin of other immune-mediated events. 
Obstaja tudi verjeten mehanizem delovanja za razvoj sarkoidoze zaradi imunomodulacijskih učinkov daklizumaba beta in vpletenosti daklizumaba beta v nastanek drugih imunsko posredovanih učinkov.
• Prior to treatment (re)start, confirmation of: o A discussion between the physician and the patient about the risk of serious and potentially fatal hepatic injury and the unpredictable nature of such reactions and about the possibility of having to switch treatment in case of levels of ALT or o Patient understanding of the risk information provided; o Receipt of a copy of the acknowledgement form; 
o pogovora med zdravnikom in bolnikom o tveganju za resne in potencialno smrtne poškodbe jeter in nepredvidljivi naravi takih reakcij in možnosti zamenjave zdravila v primeru, ko je raven AST ali ALT >3-krat ULN; o da bolnik razume posredovane informacije o tveganju;
Sodium succinate, succinic acid, sodium chloride, polysorbate 80, water for injections 
natrijev sukcinat, sukcinska kislina, natrijev klorid, polisorbat 80, voda za injekcije raztopina za injiciranje
Do not lift your pen off your injection site until the clicking sounds stop and you see green ticks in the injection status window. 
injiciranja, dokler zvok klikanja ne preneha injiciranje z mesta injiciranja, dokler zvok klikanja ne preneha in v oknu za stanje injiciranja ne zagledate zelenih kljukic.
Key effects of this IL-2 pathway modulation potentially related to the therapeutic effects of daclizumab beta in MS include selective antagonism of activated T-cell responses, and expansion of immunoregulatory CD56bright natural killer (NK) cells, which have been shown to selectively decrease activated T-cells. 
Ključni učinek te modulacije poti IL-2, ki je morda povezan s terapevtskimi učinki daklizumaba beta pri multipli sklerozi, vključuje selektivni antagonizem odzivov aktiviranih celic T in ekspanzijo imunoregulacijskih naravnih celic ubijalk CD56bright, za katere se je pokazalo, da selektivno zmanjšujejo aktivirane celice T. Ti imunomodulirajoči učinki daklizumaba beta skupaj naj bi zmanjševali patologijo osrednjega živčnega sistema pri multipli sklerozi in s tem zmanjševali pojavnost recidivov in napredovanje bolezni.
Do not use Zinbryta - if you have previously had a serious allergic reaction to any form of daclizumab, or any of the other ingredients of this medicine listed in section 6. 
Kaj morate vedeti, preden boste uporabili zdravilo Zinbryta Ne uporabljajte zdravila Zinbryta - če ste že prej imeli resne alergijske reakcije na katero koli obliko daklizumaba ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
Elimination As an IgG1 monoclonal antibody, daclizumab beta is not expected to undergo renal elimination. 
Izločanje Kot monoklonsko protitelo IgG1 se ne pričakuje, da bi se daklizumab beta izločal skozi ledvice.
There is a plausible mechanism of action for the development of this colitis due to immunomodulatory properties of daclizumab beta and involvement of daclizumab beta in the origin of other immune-mediated events. 
Obstaja verjeten mehanizem delovanja za razvoj tega kolitisa zaradi imunomodulacijskih lastnosti daklizumaba beta in vpletenosti daklizumaba beta v nastanek drugih imunsko posredovanih učinkov.
• Check that the Zinbryta medicine is colourless or slightly yellow (See Figure syringe if the liquid is cloudy, or has 
• Preverite, da je zdravilo Zinbryta brezbarvno ali rumenkasto (glejte sliko E).
The causal relationship between daclizumab beta and sarcoidosis is considered possible. 
Vzročna povezava med daklizumabom beta in sarkoidozo velja za možno.
• Patients who had failed to respond to a full and adequate course (at least 1 year) of prior DMT treatment, having had at least 1 relapse in the previous year while on therapy, and at least 9 T2 hyperintense lesions in cranial MRI or at least 1 Gd-enhancing lesion, or having an unchanged or increased relapse rate in the prior year as compared to the previous 2 years. 
DMT, ki so imeli vsaj 1 recidiv v prejšnjem letu med zdravljenjem, in vsaj 9 hiperintenzivnih lezij T2 na MR slikanju glave ali vsaj 1 lezijo, vidno z gadolinijem, ali ki so imeli nespremenjeno ali povečano stopnjo recidivov v prejšnjem letu v primerjavi s prejšnjima
• increases in body temperature (fever) 
• zvišana telesna temperatura
Daclizumab beta is not expected to undergo metabolism by hepatic enzymes such as CYP isoenzymes (see section 4.5). 
Ne pričakuje se, da bi se daklizumab beta presnavljal z jetrnimi encimi, kot so izoencimi CYP (glejte poglavje 4.5).
The active substance in Zinbryta is daclizumab beta. 
Učinkovina zdravila Zinbryta je daklizumab beta.
Colourless to slightly yellow, clear to slightly opalescent liquid with pH 6. 
raztopina za injiciranje (injekcija) Brezbarvna do rumenkasta, bistra do nekoliko motna tekočina s pH 6.
Daclizumab beta is not expected to undergo renal elimination or metabolism by hepatic enzymes (see section 4.2). 
Ne pričakuje se, da bi se daklizumab beta izločal skozi ledvice ali presnavljal z jetrnimi encimi (glejte poglavje 4.2).
• If needed, Zinbryta may be stored in the closed original carton without refrigeration up to 30°C Do not place Zinbryta pre-filled syringe back into the refrigerator after warming to room Do not freeze or expose to high temperatures. 
• Po potrebi lahko zdravilo Zinbryta do 30 dni shranjujete v zaprti originalni škatli zunaj Zdravila Zinbryta napolnjena injekcijska brizga ne dajajte nazaj v hladilnik, ko se ogreje na Ne zamrzujte in ne izpostavljajte visokim temperaturam.
The causal relationship between daclizumab beta and colitis is possible. 
Vzročna povezava med daklizumabom beta in kolitisom je možna.
Taking into account the PRAC Assessment Report on the PSUR(s) for daclizumab beta, the scientific conclusions of CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za daklizumab beta je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke: Sarkoidoza
Step 8: Disposing of the used Zinbryta Pre-filled Syringe 
8. korak: Odstranjevanje uporabljenega zdravila Zinbryta napolnjena injekcijska brizga
No studies were conducted to evaluate daclizumab beta pharmacokinetics in patients with renal or hepatic impairment. 
Študij za ovrednotenje farmakokinetike daklizumaba beta pri bolnikih z ledvično ali jetrno okvaro niso izvedli.
Zinbryta is contraindicated in patients with a history of severe hypersensitivity (e.g. anaphylaxis or anaphylactoid reactions) to all forms of daclizumab or to any of the excipients in Zinbryta (see section 
Zdravilo Zinbryta je kontraindicirano pri bolnikih s hudo preobčutljivostjo v anamnezi (npr. anafilaksija ali anafilaktične reakcije) za vse oblike daklizumaba ali katero koli pomožno snov v zdravilu Zinbryta, navedeno v poglavju 6.1.
The exact metabolic pathway for daclizumab beta has not been characterised. 
Natančne poti presnavljanja daklizumaba beta niso opisali.
Contact your doctor immediately. 
Potem morate stopiti v stik z zdravnikom,
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Zinbryta 150 mg injection daclizumab beta 
IME ZDRAVILA IN POT(I) UPORABE Zinbryta 150 mg injekcija daklizumab beta s.c.
• If needed, Zinbryta may be stored in the closed original carton without refrigeration up to 30°C 
• Po potrebi lahko zdravilo Zinbryta do 30 dni shranjujete v zaprti originalni škatli zunaj hladilnika pri temperaturi do 30 °C.
- at least monthly blood tests during treatment, as close as possible before each dose of Zinbryta, and more often if your doctor decides this is necessary - tests for up to 6 months after stopping treatment. 
- opravljati vsaj mesečne krvne preiskave med zdravljenjem kolikor mogoče neposredno pred vsakim odmerkom zdravila Zinbryta, ali še pogosteje, če zdravnik odloči, da je to potrebno,
Daclizumab beta has not been studied in patients with renal impairment. 
Daklizumaba beta niso preučevali pri bolnikih z okvaro ledvic.
You will hear the 
Slišali boste, ko se bo začelo klikanje.
The active substance is daclizumab beta. 
Učinkovina je daklizumab beta.
Multipack: 3 (3 packs of 1) pre-filled syringes. 
Skupno pakiranje: 3 (3 pakiranja z 1) napolnjene injekcijske brizge Skupno pakiranje: 3 (3 pakiranja z 1) napolnjeni injekcijski peresniki subkutana uporaba
• decreases in the amount of white blood cells (these will show up in blood tests) 
• okužba kože (folikulitis, akne) • zmanjšano število belih krvnih celic (to pokažejo krvne preiskave)
Low red blood cell counts (autoimmune haemolytic anaemia): (Uncommon - may affect up to 1 in 100 people) 
• spremembe na krvi (anemija), zaradi česar ste lahko šibki Občasni neželeni učinki (Pojavijo se lahko pri največ 1 od 100 bolnikov)
Daclizumab beta has not been studied in patients with hepatic impairment. 
Daklizumaba beta niso preučevali pri bolnikih z okvaro jeter.
General Warnings Do not reuse Zinbryta pre-filled syringe. 
Splošna opozorila Zdravila Zinbryta napolnjena injekcijska brizga ne uporabite ponovno.
(See Figure J.) 
(Glejte sliko I.)
• Zinbryta pre-filled syringe is for injecting the medicine under the skin only (subcutaneous). 
• Zdravilo Zinbryta napolnjena injekcijska brizga je samo za injiciranje zdravila pod kožo
You could get a needle injury or the pen may lock. 
Lahko se poškodujete z iglo ali pa se napolnjeni Peresnika ne pokrivajte ponovno, ko je
• However, if it is more than 2 weeks from your missed dose, skip the missed dose and take your 
• Če od izpuščenega odmerka mineta več kot 2 tedna, pozabljeni odmerek izpustite in si dajte naslednji odmerek na vaš običajni dan.
• inflamed or enlarged lymph nodes (lymphadenopathy, lymphadenitis) 
• zvišana telesna temperatura (vročina) • vnete ali povečane bezgavke (limfadenopatija, limfadenitis)
QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 150 mg of daclizumab beta in 1 mL solution for injection. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena napolnjena injekcijska brizga vsebuje 150 mg daklizumaba beta v 1 ml raztopine za injiciranje.
• Keep Zinbryta pre-filled syringe and all medicines out of reach and sight of children. 
• Zdravilo Zinbryta napolnjena injekcijska brizga in vsa zdravila shranjujte nedosegljiva
Immune system disorders 
Bolezni imunskega sistema sarkoidoza občasni
Solution for injection 
Injiciranje zdravila
Step 2: Check The Zinbryta Pre-filled Syringe 
2. korak: Preglejte zdravilo Zinbryta napolnjena injekcijska brizga • Preverite rok uporabnosti zdravila
Zinbryta 150 mg solution for injection in pre-filled syringe Zinbryta 150 mg solution for injection in pre-filled pen daclizumab beta 
Zinbryta 150 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Zinbryta 150 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku daklizumab beta
• Check with your doctor, pharmacist or nurse about the right way to throw away the used syringe. 
• O pravilnem načinu odstranjevanja uporabljenega napolnjenega injekcijskega peresnika se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Serious liver problems can occur both early after starting treatment with Zinbryta, any time during treatment and several months after discontinuing treatment. 
Resne težave z jetri se lahko pojavijo kmalu po začetku jemanja zdravila Zinbryta,
Each pre-filled pen contains a pre-filled syringe, containing 150 mg of daclizumab beta in 1 mL solution for injection. 
En napolnjen injekcijski peresnik vsebuje eno napolnjeno injekcijsko brizgo, ki vsebuje 150 mg daklizumaba beta v 1 ml raztopine za injiciranje.
Do not place Zinbryta pen back into the refrigerator after warming to room temperature. 
Zdravila Zinbryta napolnjen injekcijski peresnik ne dajajte nazaj v hladilnik, ko se ogreje na sobno temperaturo.
This includes any possible side effects not listed 
Možni neželeni učinki
Do not re-cap the pen. 
Injekcijskega peresnika ne smete ponovno pokrivati s pokrovčkom.
• Very common (≥ 1/10) 
• zelo redki (<1/10.000)
Each pre-filled syringe contains 150 mg of daclizumab beta in 1 mL solution for injection. 
En napolnjen injekcijski peresnik vsebuje 150 mg daklizumaba beta v 1 ml raztopine za injiciranje.
psoriasis) 
Imunogenost).
Do not inject into an area of your body where the skin is irritated, red, bruised, tattooed, infected, or scarred. 
Izberite mesto injiciranja na stegnu, trebuhu ali zadnji strani nadlahti (glejte poudarjene o Če nekatere predele pretežko dosežete, prosite usposobljenega negovalca, naj vam Ne injicirajte v telesni predel, kjer je koža modrice, tetovaže, okužbe ali brazgotine.
Check the medicine window and make sure the Zinbryta medicine is colourless to 
Preverite okno za zdravilo in se prepričajte,
The needle cover will extend to cover the needle and will lock (See Figure I). 
Varovalo igle bo pokrilo iglo in
The procedure started on 2 June 2006. 
Postopek se je začel 2. junija 2006.
London, 29 May 2007 Doc.Ref. 
London, 29. maj 2007 Dok.ref.
A Decision was issued by the European Commission on 29 May 2007. 
Evropska Komisija je sklep izdala dne 29. maja 2007.
The Marketing Authorisation Holder provided supplementary information on 21 September 2006 and 12 January 2007. 
Imetnik dovoljenja za promet z zdravilom je dodatne informacije predložil 21. septembra 2006 in 12. januarja 2007.
EMEA/144030/2007 
EMEA/CHMP/274921/2007
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 30 REFERRAL FOR Xefo and associated names International Non-Proprietary Name (INN): lornoxicam 
ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 30 ZA Xefo in z njim povezana imena Mednarodno nelastniško ime (INN): lornoxicam
On 16 May 2006 Nycomed Denmark Aps presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, in order to harmonise the nationally authorised Summaries of Product Characteristics (SPC), Package Leaflets and Labelling of the medicinal product Xefo and associated names. 
Družba Nycomed Danmark Aps je dne 16. maja 2006 agenciji EMEA predložila napotitev v skladu s členom 30 Direktive 2001/83/ES, da bi uskladila na nacionalni ravni odobrene povzetke glavnih značilnosti zdravila (SPC), navodila za uporabo ter označevanje zdravila Xefo in z njim povezanih imen.
Xefo and associated names, 4mg and 8mg film-coated tablets, 8mg rapid film coated tablet, and 8mg powder and solvent for solution for injection, is a non-steroidal anti-inflammatory drug (NSAID), used for short-term relief of acute mild to moderate pain, symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis. 
Zdravilo Xefo in z njim povezana imena, 4 mg in 8 mg filmsko obložene tablete, 8 mg filmsko obložene hitro delujoče tablete ter 8 mg prašek in vehikel za raztopino za injiciranje, je nesteroidno protivnetno zdravilo (NSPVZ), ki se uporablja za kratkotrajno blaženje akutnih blagih do zmerno hudih bolečin, simptomatsko blaženje bolečin in vnetij pri osteoartritisu ter simptomatsko blaženje bolečin in vnetij pri revmatoidnem artritisu.
The basis for referral was that there were divergences in the Summaries of Product Characteristics of Xefo and associated names approved across EU Member States, with respect to the short-term relief of acute mild to moderate pain, symptomatic relief of pain and inflammation in osteoarthritis and symptomatic relief of pain and inflammation in rheumatoid arthritis. 
Osnova za napotitev so bile razlike v povzetkih glavnih značilnosti za zdravilo Xefo in z njim povezanih imen, ki so bili odobreni v državah članicah EU, v zvezi s kratkotrajnim blaženjem akutnih blagih do zmernih bolečin, simptomatskim blaženjem bolečin in vnetij pri osteoartritisu in simptomatskim blaženjem bolečin in vnetij pri revmatoidnem artritisu.
During its February 2007 meeting, the CHMP, in the light of the overall submitted data and the scientific discussion within the Committee, was of the opinion that the proposal for the harmonisation of the SPC, Labelling and Package leaflet was acceptable and that they should be amended. 
Na seji februarja 2007 se je CHMP na osnovi vseh predloženih podatkov in znanstvene razprave v odboru odločil, da je predlog za uskladitev Povzetka glavnih značilnosti zdravila, označevanja in Navodila za uporabo sprejemljiv in da bi jih bilo treba dopolniti.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amended SPC, labelling and package leaflet in Annex III. 
Seznam zadevnih imen izdelkov je podan v Dodatku I. Znanstveni zaključki so na voljo v Dodatku II, dopolnjeni Povzetek glavnih značilnosti zdravila, označevanje in Navodilo za uporabo pa v Dodatku III.
The CHMP gave a positive opinion on 22 February 2007 recommending the harmonisation of the SPC, labelling and package leaflet for Xefo and associated names. 
CHMP je dne 22. februarja 2007 podal pozitivno mnenje in priporočil uskladitev Povzetka glavnih značilnosti zdravila, označevanja in Navodila za uporabo za zdravilo Xefo in z njim povezana imena.
Further information on Atripla can be found on the Agency's website ema.europa.eu/en/medicines/human/EPAR/Atripla. 
Nadaljnje informacije o zdravilu NexGard so na voljo na spletni strani agencije: ema.europa.eu/en/medicines/human/EPAR/Atripla.
• medicines that cause QT prolongation; 
• zdravila, ki povzročajo podaljšanje intervala QT,
Other information about Atripla 
Druge informacije o zdravilu Atripla
What measures are being taken to ensure the safe use of Atripla? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Atripla?
In the European Union (EU), efavirenz has been approved since 1999, emtricitabine has been approved since 2003, and tenofovir disoproxil has been approved since 2002. 
V Evropski uniji (EU) je efavirenz odobren od leta 1999, emtricitabin od leta 2003, dizoproksiltenofovirat pa od leta 2002.
Atripla received a marketing authorisation valid throughout the EU on 13 December 2007. 
Za zdravilo Atripla je bilo 13. decembra 2007 izdano dovoljenje za promet, veljavno po vsej EU.
Patients should take the medicine regularly and not miss doses. 
Bolniki morajo zdravilo jemati redno in odmerkov ne smejo izpuščati.
The Agency decided that Atripla's benefits are greater than its risks and recommended that it can be authorised for use in the EU. 
Agencija je zaključila, da so koristi zdravila Atripla večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
Side effects reported with Atripla are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Atripla, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
As for all medicines, data on the use of Atripla are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Atripla stalno spremljajo.
An overview of Atripla and why it is authorised in the EU 
Pregled zdravila Atripla in zakaj je odobreno v EU
Atripla (efavirenz / emtricitabine / tenofovir disoproxil) 
Atripla (efavirenz/emtricitabin/dizoproksiltenofovirat)
What is Atripla and what is it used for? 
Kaj je zdravilo Atripla in za kaj se uporablja?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Atripla have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Atripla upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Atripla keeps the amount of HIV in the blood at a low level. 
Zdravilo Atripla ohranja nizko raven virusa HIV v krvi.
Why is Atripla authorised in the EU? 
Zakaj je bilo zdravilo Atripla odobreno v EU?
The European Medicines Agency noted that Atripla needs to be taken on an empty stomach to prevent certain side effects of one of its components, efavirenz. 
Evropska agencija za zdravila je ugotovila, da je treba zdravilo Atripla jemati na prazen želodec, da se preprečijo določeni neželeni učinki ene od njegovih učinkovin, efavirenza.
Another study, which looked at how the combined tablet was absorbed in the body, showed that the combination tablet was absorbed in the same way as the separate medicines, when they were taken on an empty stomach. 
Druga študija, v kateri so proučevali, kako se kombinirana tableta absorbira v telesu, je pokazala, da se je ta absorbirala enako kot ločena zdravila, kadar so bila vzeta na prazen želodec.
The main measure of effectiveness was the proportion of patients whose viral loads were below 200 copies/ml after 48 weeks. 
Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih je bilo virusno breme po 48 tednih manj kot 200 kopij/ml.
The company that markets Atripla will ensure that all doctors expected to prescribe the medicine are provided with an educational pack that includes information on the increased risk of kidney disease with medicines containing tenofovir disoproxil such as Atripla. 
Družba, ki trži zdravilo Atripla, bo zagotovila, da bodo vsi zdravniki, ki naj bi predpisovali to zdravilo, prejeli izobraževalno gradivo, ki bo vsebovalo informacije o povečanem tveganju za nastanek ledvične bolezni pri zdravilih, ki vsebujejo dizoproksiltenofovirat, kot je na primer zdravilo Atripla.
What benefits of Atripla have been shown in studies? 
Kakšne koristi je zdravilo Atripla izkazalo v študijah?
• voriconazole (used to treat fungal infections). 
• vorikonazol (ki se uporablja za zdravljenje glivičnih okužb).
It must not be used in patients in whom previous HIV treatment combinations have not worked or have stopped working. 
Ne sme se uporabljati pri bolnikih, pri katerih predhodna kombinirana zdravljenja okužbe z virusom HIV bodisi niso bila učinkovita bodisi so prenehala biti učinkovita.
What are the risks associated with Atripla? 
Kakšna tveganja so povezana z zdravilom Atripla?
The most common side effects with Atripla (which may affect more than 1 patient in 10) are dizziness, headache, diarrhoea, nausea (feeling sick), vomiting, rash, asthenia (weakness), hypophosphataemia (low blood levels of phosphates) and elevated levels of creatine kinase (an enzyme found in muscles). 
Najpogostejši neželeni učinki zdravila Atripla (ki se lahko pojavijo pri več kot 1 bolniku od 10) so omotica, glavobol, driska, navzeja (siljenje na bruhanje), bruhanje, izpuščaj, astenija (šibkost), hipofosfatemija (nizka raven fosfatov v krvi) in zvišana raven kreatin kinaze (encima, prisotnega v mišicah).
For more information about using Atripla, see the package leaflet or contact a doctor or pharmacist. 
Za več informacij glede uporabe zdravila Atripla glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
After 48 weeks, 89% of the patients taking Atripla (181 out of 203) and 88% of those remaining on previous treatment (85 out of 97) had viral loads below 200 copies/ml. 
Po 48 tednih je imelo virusno breme pod 200 kopij/ml 89 % (181 od 203) bolnikov, ki so jemali zdravilo Atripla, in 88 % (85 od 97) bolnikov, ki so nadaljevali prejšnje zdravljenje.
• certain medicines whose breakdown is blocked or accelerated by Atripla; 
• določena zdravila, pri katerih zdravilo Atripla zavira ali pospešuje njihova okvara njihovo razgradnjo,